< Back to previous page
Researcher
Pieter Gillard
- Disciplines:Endocrinology and metabolic diseases
Affiliations
- Clinical and Experimental Endocrinology (Division)
Member
From1 Oct 2009 → Today
Projects
1 - 10 of 11
- Assessing novel technologies and glucometrics to improve glucose control and quality of life of people with type 1 diabetesFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Technological improvements in the management of type 1 diabetesFrom1 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The road to personalized management of type 1 diabetes with a focus on closed-loop devicesFrom2 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The use of novel technologies with a focus on the individual needs of people living with type 1 diabetesFrom1 Oct 2020 → 30 Sep 2021Funding: BOF - postdoctoral mandates
- Closed-loop insulin delivery in pregnant women with type 1 diabetes (the CRISTAL study)From1 Oct 2020 → TodayFunding: FWO Strategic Basic Research Grant, BOF - doctoral mandates
- Exploring the use of continuous glucose monitoring to improve glycemic control and quality of life in type 1 diabetesFrom1 Jan 2019 → 31 Mar 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Histology: a vital tool for endocrine and metabolic researchFrom1 Oct 2016 → 30 Sep 2018Funding: Fund Recuperation Fiscal Exemption
- Identification of patient-specific parameters for bolus calculators in type 1 diabetic patientsFrom15 Aug 2016 → 31 Dec 2020Funding: FWO Strategic Basic Research Grant
- Robust identification of patient-specific parameters for bolus calculators in type 1 diabetic patientsFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- The beta-cell and the immune system in type 1 diabetes: partners in crime - developing new therapies in type 1 diabetes through better understanding of beta-cell behaviour and use of novel immunomodulators.From1 Oct 2013 → 30 Sep 2018Funding: BOF - Concerted Research Project from 1994
Publications
1 - 10 of 116
- Pseudohyperglycemia due to glucometer interference in galactosemia(2024)
Authors: Bram Decru, Gunnar Naulaers, Christine Vanhole, Daisy Rymen, Peter Witters, Pieter Gillard, Pieter Vermeersch
- Cost-utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium(2024)
Authors: Astrid Van Muylder, Jeroen Luyten, Pieter Gillard
- The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review(2024)
Authors: Chantal Mathieu, Pieter Gillard
Pages: 66 - 75 - Hypoglycaemia after Initiation of CFTR Modulator Therapy in a Cystic Fibrosis Patient without Diabetes(2023)
Authors: Lieven Dupont, Natalie Lorent, Pieter Gillard, Bart Van Der Schueren, Ann Mertens, Chantal Mathieu, Roman Vangoitsenhoven
- Insulin pump technology for patients with alcoholism: a dangerous combination or worth a try?(2023)
Authors: Pieter Gillard
Pages: 1 - 5 - Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes(2023)
Authors: Pieter Gillard
- Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review(2023)
Authors: Pieter Gillard, Chantal Mathieu
- Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine(2023)
Authors: Pieter Gillard, Nele Steenackers, Bart Van Der Schueren, Chantal Mathieu
Pages: 2438 - 2457 - Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study (vol 45, pg 888, 2022)(2023)
Authors: Pieter Gillard
Pages: 1721 - 1721 - Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of responders(2023)
Authors: Pieter Gillard